Business
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on clinical programs
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n\nEnrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer\n\n\n\nEnrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors\n\n\n\nUpdate on clinical programs expected in 2024\n\n\n\n$349.7 million in cash, cash equivalents, and short-term investments at end of third quarter 2023\n\n\n\nCash and investments projected to support current operating plan through 2027 to generate Phase 1b data for our PSMA and EGFR-TRACTr programs\n\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.\n\n\n“We are pleased with the enrollment in the two clinical studies for our PSMA-TRACTr JANX007 and our EGFR-TRACTr JANX008,” said David Campbell, Ph.D., President and CEO of Janux. “As we enter 2024, equipped with a strong financial foundation, we are committed to advancing these clinical programs and expanding our pipeline so that we can rapidly bring forward new meaningful therapies for cancer patients.”\n\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\n\n\nPSMA-TRACTr (JANX007) continues to enroll in the first-in-human Phase 1 clinical trial in mCRPC (NCT05519449).\n\n\n\nEGFR-TRACTr (JANX008) continues to enroll in the first-in-human Phase 1 clinical trial in advanced or metastatic solid tumors (NCT05783622).\n\n\n\nPD-L1xCD28 TRACIr (JANX009) IND-enabling studies completed.\n\n\n\nTROP2-TRACTr development candidate identification completed.\n\n\n\nJanux anticipates providing an update on its clinical programs in 2024.\n\n\nTHIRD QUARTER 2023 FINANCIAL HIGHLIGHTS:\n\n\n\nCash and cash equivalents and short-term investments: As of September 30, 2023, Janux reported cash and cash equivalents and short-term investments of $349.7 million compared to $327.0 million at December 31, 2022, which we project will be sufficient to fund our current operating plan through 2027 to generate Phase 1b data for our PSMA and EGFR-TRACTr programs.\n\n\n\nResearch and development expenses: For the quarter ended September 30, 2023, Janux reported research and development ex...